Equities Analysts Issue Forecasts for BEAM FY2026 Earnings

Beam Therapeutics Inc. (NASDAQ:BEAM) – Equities researchers at Cantor Fitzgerald issued their FY2026 earnings estimates for Beam Therapeutics in a research note issued on Monday, June 9th. Cantor Fitzgerald analyst R. Bienkowski expects that the company will post earnings per share of ($2.92) for the year. Cantor Fitzgerald currently has a “Overweight” rating on the stock. The consensus estimate for Beam Therapeutics’ current full-year earnings is ($4.57) per share.

BEAM has been the subject of a number of other research reports. HC Wainwright reaffirmed a “buy” rating and issued a $80.00 target price on shares of Beam Therapeutics in a research report on Monday, April 7th. Jones Trading upgraded shares of Beam Therapeutics from a “hold” rating to a “buy” rating and set a $34.00 price objective on the stock in a research note on Monday, March 10th. Barclays lowered their price objective on shares of Beam Therapeutics from $31.00 to $25.00 and set an “equal weight” rating on the stock in a research note on Wednesday, May 7th. Guggenheim lowered their price objective on shares of Beam Therapeutics from $78.00 to $55.00 and set a “buy” rating on the stock in a research note on Wednesday, May 7th. Finally, Wedbush restated an “outperform” rating and set a $57.00 price objective on shares of Beam Therapeutics in a research note on Monday, March 10th. Two research analysts have rated the stock with a hold rating, eleven have issued a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Buy” and an average target price of $48.75.

Beam Therapeutics Trading Down 1.1%

Beam Therapeutics stock opened at $17.89 on Wednesday. The company has a market cap of $1.80 billion, a P/E ratio of -10.16 and a beta of 2.08. Beam Therapeutics has a 1-year low of $13.53 and a 1-year high of $35.25. The company has a fifty day simple moving average of $17.47 and a 200 day simple moving average of $23.18.

Beam Therapeutics (NASDAQ:BEAM) last issued its quarterly earnings data on Tuesday, May 6th. The company reported ($1.24) EPS for the quarter, missing analysts’ consensus estimates of ($1.11) by ($0.13). Beam Therapeutics had a negative return on equity of 16.22% and a negative net margin of 41.07%. The company had revenue of $7.47 million for the quarter, compared to analyst estimates of $14.69 million. During the same quarter in the previous year, the business earned ($1.21) earnings per share. The company’s revenue was up 1.4% on a year-over-year basis.

Insider Activity

In related news, insider Christine Bellon sold 5,674 shares of the stock in a transaction dated Tuesday, April 1st. The shares were sold at an average price of $18.35, for a total transaction of $104,117.90. Following the completion of the transaction, the insider now owns 117,294 shares in the company, valued at approximately $2,152,344.90. This represents a 4.61% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO John M. Evans sold 30,663 shares of the stock in a transaction dated Tuesday, April 1st. The shares were sold at an average price of $18.35, for a total transaction of $562,666.05. Following the transaction, the chief executive officer now owns 986,249 shares of the company’s stock, valued at approximately $18,097,669.15. The trade was a 3.02% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 43,771 shares of company stock worth $803,198 over the last quarter. Insiders own 3.50% of the company’s stock.

Hedge Funds Weigh In On Beam Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Wealthfront Advisers LLC bought a new position in Beam Therapeutics during the fourth quarter worth about $41,000. GF Fund Management CO. LTD. bought a new position in Beam Therapeutics during the fourth quarter worth about $43,000. CWM LLC boosted its position in Beam Therapeutics by 79.8% during the first quarter. CWM LLC now owns 2,684 shares of the company’s stock worth $52,000 after purchasing an additional 1,191 shares during the period. Sterling Capital Management LLC boosted its position in Beam Therapeutics by 816.0% during the fourth quarter. Sterling Capital Management LLC now owns 2,409 shares of the company’s stock worth $60,000 after purchasing an additional 2,146 shares during the period. Finally, Amalgamated Bank boosted its position in Beam Therapeutics by 20.4% during the first quarter. Amalgamated Bank now owns 3,153 shares of the company’s stock worth $62,000 after purchasing an additional 534 shares during the period. Institutional investors own 99.68% of the company’s stock.

About Beam Therapeutics

Beam Therapeutics Inc, a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a.